Recombinant Human CD19 Fc Chimera Biotinylated Protein, CF

Name: Recombinant Human CD19 Fc Chimera Biotinylated Protein, CF
Brand: R&D Systems
SKU: BT9269
Price: 632 USD
Availability: InStock

R&D Systems | Catalog # BT9269

Submit a review

Product Documents

100% Guarantee

Product Specifications
Scientific Data
Preparation & Storage
Calculators
Background
Product Documents
Specific Notices
Research Areas

Key Product Details

R&D Systems CHO-derived Recombinant Human CD19 Fc Chimera Biotinylated Protein (BT9269)
Quality control testing to verify active proteins with lot specific assays by in-house scientists
All R&D Systems proteins are covered with a 100% guarantee

Source

CHO

Structure / Form

Disulfide linked homodimer, Biotinylated via amines

Conjugate

Biotin

Applications

Bioactivity

View all CD19 Proteins and Enzymes »

Product Specifications

Source

Chinese Hamster Ovary cell line, CHO-derived human CD19 protein

Human CD19 (Glu21-Lys291) Accession # P15391	IEGRMD	Human IgG₁ (Pro100-Lys330)
N-terminus		C-terminus

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Glu21

Predicted Molecular Mass

57 kDa

SDS-PAGE

75-90 kDa, under reducing conditions

Activity

Measured by its binding ability in a functional ELISA.
Biotinylated Recombinant Human CD19 Fc Chimera binds to Human CD19 Antibody (Catalog # MAB4867) with an ED₅₀ of 25.0-250 ng/mL.

Scientific Data Images for Recombinant Human CD19 Fc Chimera Biotinylated Protein, CF

Biotinylated Recombinant Human CD19 Fc Chimera Protein Binding Activity.

Measured by its binding ability in a functional ELISA. Biotinylated Recombinant Human CD19 Fc Chimera (Catalog # BT9269) binds to Human CD19 Antibody (MAB4867) with an ED₅₀ of 25.0-250 ng/mL.

Biotinylated Recombinant Human CD19 Fc Chimera Protein SDS-PAGE.

2 μg/lane of Biotinylated Recombinant Human CD19 Fc Chimera Protein (Catalog # BT9269) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 75-90 kDa and 150-180 kDa, respectively.

Formulation, Preparation, and Storage

BT9269

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution	Reconstitute at 500 μg/mL in water.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Calculators

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Background: CD19

CD19 protein is a 95 kDa transmembrane glycoprotein that plays a central role in B cell activation and humoral immune responses (1, 2). CD19 is expressed throughout B cell development from pre-B cells through mature B cells, and it is commonly used as a B cell lineage marker (1). It is required for the responsiveness of mature B cell to antigen stimulation, germinal center development, and antibody affinity maturation (4, 5). The CD19 protein associates with the B cell antigen receptor (BCR), CD81, CD38, CD21, CD22, and IFITM1/CD225/Leu13, (6-9). These associations enable CD19 to amplify B cell signaling (7, 9-12) and reduce the threshold for antigen stimulation through the BCR (13). CD19 polymorphisms and up-regulation can lead to the development of autoimmunity by promoting autoantibody production (2). CD19 has emerged as promising therapeutic target for hematologic cancers and solid tumors. Immunotherapy using a chimeric antigen receptor (CAR) targeting CD19 has proven effective in many different cancers. The first CD19 CAR T cell therapies have been granted FDA approval for the treatment of B cell malignancies with several more in clinical trials. Mature human CD19 protein consists of a 272 amino acid (aa) extracellular domain (ECD) with two Ig-like domains, a 22 aa transmembrane segment, and a 243 aa cytoplasmic domain (3). Within the ECD, human CD19 shares 57% amino acid sequence identity with mouse and rat CD19.